Our data suggest that TGF-β/Smad3-mediated tumor-suppression plays an important role in the natural history of ER+ breast cancer, and that tumor-suppressive effects of TGF-β are still evident in the tumor at the time of surgery and influencing disease outcome for a significant fraction of patients. The gene discussed is SMAD3; the disease is breast carcinoma.